{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:11:58Z","timestamp":1787962318965,"version":"build-2784847793"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for Health and Care Research\u2014Health Technology Assessment","award":["NIHR130580"],"award-info":[{"award-number":["NIHR130580"]}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To explore the acceptability of an individualized risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adults (\u226518\u2009years) taking immune-suppressing treatment(s) for at least six months, and healthcare professionals (HCPs) with experience of either prescribing and\/or monitoring immune-suppressing drugs were invited to participate in a single, remote, one-to-one, semi-structured interview. Interviews were conducted by a trained qualitative researcher and explored their views and experiences of current monitoring and acceptability of a proposed risk-stratified monitoring plan. Interviews were transcribed verbatim and inductively analysed using thematic analysis in NVivo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighteen patients and 13 HCPs were interviewed. While participants found monitoring of immune-suppressing drugs with frequent blood-tests reassuring, the current frequency of these was considered burdensome by patients and HCPs alike, and to be a superfluous use of healthcare resources. Given abnormalities rarely arose during long-term treatment, most felt that monitoring blood-tests were not needed as often. Patients and HCPs found it acceptable to increase the interval between monitoring blood-tests from three-monthly to six-monthly or annually depending on the patients\u2019 risk profiles. Conditions of accepting such a change included: allowing for clinician and patient autonomy in determining individuals\u2019 frequency of monitoring blood-tests, the flexibility to change monitoring frequency if someone\u2019s risk profile changed, and endorsement from specialist societies and healthcare providers such as the National Health Service.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A risk-stratified approach to monitoring was acceptable to patients and health care professionals. Guideline groups should consider these findings when recommending blood-test monitoring intervals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae175","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T14:15:58Z","timestamp":1710425758000},"page":"969-975","source":"Crossref","is-referenced-by-count":5,"title":["Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-1816","authenticated-orcid":false,"given":"Amy","family":"Fuller","sequence":"first","affiliation":[{"name":"Academic Rheumatology, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Hancox","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Loughborough University , Loughborough,","place":["UK"]},{"name":"Lifespan and Population Health, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hywel C","family":"Williams","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Card","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9065-212X","authenticated-orcid":false,"given":"Maarten W","family":"Taal","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research and Innovation, Translational Medical Sciences, University of Nottingham , Derby,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P","family":"Aithal","sequence":"additional","affiliation":[{"name":"Nottingham Digestive Diseases Centre, Translational Medical Sciences, University of Nottingham , Nottingham,","place":["UK"]},{"name":"NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and The University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Fox","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2677-1028","authenticated-orcid":false,"given":"Christian D","family":"Mallen","sequence":"additional","affiliation":[{"name":"Primary Care Centre Versus Arthritis, Keele University , Keele,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bingham","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust , Norwich,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Vedhara","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, University of Nottingham , Nottingham,","place":["UK"]},{"name":"School of Psychology, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, School of Medicine, University of Nottingham , Nottingham,","place":["UK"]},{"name":"NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and The University of Nottingham , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2025030500183528400_keae175-B1","first-page":"736","article-title":"Rheumatoid arthritis is getting less frequent-results of a nationwide population-based cohort study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025030500183528400_keae175-B2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1053\/j.gastro.2003.09.027","article-title":"Inflammatory bowel disease and the risk of fracture","volume":"125","author":"van Staa","year":"2003","journal-title":"Gastroenterology"},{"key":"2025030500183528400_keae175-B3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjd.15021","article-title":"Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study","volume":"176","author":"Springate","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025030500183528400_keae175-B4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/key156","article-title":"Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study","volume":"57","author":"Nakafero","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025030500183528400_keae175-B5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean","year":"2014","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025030500183528400_keae175-B6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/annrheumdis-2014-206334","article-title":"The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012","volume":"75","author":"Rees","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025030500183528400_keae175-B7","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"2025030500183528400_keae175-B8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/kew479","article-title":"BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs","volume":"56","author":"Ledingham","year":"2017","journal-title":"Rheumatology"},{"key":"2025030500183528400_keae175-B9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.1780390503","article-title":"Guidelines for monitoring drug therapy in rheumatoid arthritis","volume":"39","author":"American College of Rheumatology Ad Hoc Committee on Clinical Guidelines","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025030500183528400_keae175-B10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2025030500183528400_keae175-B11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/bjd\/ljad430","article-title":"Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies","volume":"190","author":"Abhishek","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025030500183528400_keae175-B12","doi-asserted-by":"crossref","first-page":"102213","DOI":"10.1016\/j.eclinm.2023.102213","article-title":"Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation","volume":"64","author":"Nakafero","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025030500183528400_keae175-B13","doi-asserted-by":"crossref","first-page":"rkac046","DOI":"10.1093\/rap\/rkac046","article-title":"Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum","volume":"6","author":"Nakafero","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"2025030500183528400_keae175-B14","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1093\/rheumatology\/keab254","article-title":"What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?","volume":"60","author":"Nakafero","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500183528400_keae175-B15","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/rheumatology\/keab790","article-title":"Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum","volume":"61","author":"Nakafero","year":"2022","journal-title":"Rheumatology (Oxford, England)"},{"key":"2025030500183528400_keae175-B16","doi-asserted-by":"crossref","first-page":"e074678","DOI":"10.1136\/bmj-2022-074678","article-title":"Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK","volume":"381","author":"Nakafero","year":"2023","journal-title":"BMJ"},{"key":"2025030500183528400_keae175-B17","doi-asserted-by":"crossref","first-page":"e003980","DOI":"10.1136\/rmdopen-2023-003980","article-title":"Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation","volume":"10","author":"Abhishek","year":"2024","journal-title":"RMD Open"},{"key":"2025030500183528400_keae175-B18","author":"Abhishek","year":"2023"},{"key":"2025030500183528400_keae175-B19","volume-title":"Nursing research: generating and assessing evidence for nursing practice","author":"Polit","year":"2008","edition":"8th edn."},{"key":"2025030500183528400_keae175-B20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"2025030500183528400_keae175-B21","doi-asserted-by":"crossref","first-page":"e0245112","DOI":"10.1371\/journal.pone.0245112","article-title":"Decreasing patient-reported burden of treatment: a systematic review of quantitative interventional studies","volume":"16","author":"Lesage","year":"2021","journal-title":"PloS one"},{"key":"2025030500183528400_keae175-B22","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","article-title":"Saturation in qualitative research: exploring its conceptualization and operationalization","volume":"52","author":"Saunders","year":"2018","journal-title":"Qual Quant"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae175\/57237855\/keae175.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/969\/57237855\/keae175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/969\/57237855\/keae175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:21:19Z","timestamp":1741134079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/969\/7628623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,14]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae175","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,3,14]]}}}